Key Highlights

  • Rapport Therapeutics shares are trading at $34.24 in Wednesday's session, down 17.43%.
  • The decline comes as investors book profits ahead of a closely watched Phase 2 bipolar mania readout for lead candidate RAP-219.
  • Multiple research firms reiterated positive ratings today, including price targets as high as $80, with several citing rising probability of trial success.
  • Shares had run up roughly 56% over the past year heading into today's session, fueling the sharp pullback as some investors lock in gains ahead of the binary catalyst.

Profit-Taking Ahead of a Binary Catalyst

Rapport Therapeutics (NASDAQ:RAPP) shares are sinking in Wednesday's session as investors book profits ahead of the closely watched Phase 2 bipolar mania readout for lead candidate RAP-219, despite a wave of bullish analyst commentary released the same day. One research firm reiterated a positive rating with an $80 price target, and another reiterated a bullish rating with a $75 price target, both citing rising probability of trial success and RAP-219's potential in bipolar mania and epilepsy. Several additional research firms also reiterated positive ratings today.

A Precision Neuroscience Pipeline Built Around AMPA Receptors

Rapport Therapeutics is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on discovering and developing precision small-molecule medicines for central nervous system disorders. Its lead candidate, RAP-219, is designed to selectively inhibit TARP gamma-8-containing AMPA receptors with picomolar potency, targeting focal epilepsy, peripheral neuropathic pain and bipolar disorder, while a second candidate, RAP-199, offers a differentiated profile against the same target.

Valuation Already Reflects High Expectations

A separate research note cautioned that despite the strong underlying science, current valuation already prices in significant success, with shares up roughly 56% over the past year heading into today's session. That combination of an approaching binary catalyst and a valuation that already reflects high expectations for RAP-219 helps explain why some investors are locking in gains now rather than waiting for the readout itself. Founded in 2022 and led by CEO Abraham N. Ceesay, Rapport completed its IPO in June 2024 and remains a pre-revenue company advancing its pipeline toward key data.